Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension

BACKGROUND: Pulmonary arterial hypertension is a progressive and life-threatening disorder characterized by elevated pulmonary arterial pressure, right ventricular hypertrophy, and eventual right heart failure. Omaveloxolone, an orally bioavailable synthetic triterpenoid recently approved for Friedreich's ataxia, improves mitochondrial bioenergetics and restores redox homeostasis. We investigated whether pharmacological activation of NRF2 (nuclear factor erythroid 2-related factor 2) by Omaveloxolone confers therapeutic benefit in pulmonary hypertension (PH). METHODS: The effects of Omaveloxolone were evaluated in chronic hypoxia-induced PH in mice, monocrotaline-induced PH in rats, and sugen/hypoxia-induced PH in rats, together with studies in human pulmonary artery endothelial and smooth muscle cells. RESULTS: NRF2 expression and nuclear localization were reduced in PH lungs and hypoxia-exposed cells, whereas Omaveloxolone restored NRF2 activity and increased downstream antioxidant enzymes. In endothelial cells, Omaveloxolone reduced oxidative stress, suppressed inflammatory signaling, and inhibited endothelial-to-mesenchymal transition. In smooth muscle cells, it attenuated oxidative stress and normalized abnormal proliferation, migration, and apoptosis. Omaveloxolone reduced HIF (hypoxia-inducible factor)-2α accumulation in endothelial cells and inhibited HIF-1α stabilization in smooth muscle cells. NRF2 knockdown attenuated these effects, supporting pathway dependency. Omaveloxolone attenuated PH, reduced right ventricular hypertrophy and vascular remodeling, and improved right ventricular function across hypoxia, monocrotaline, and sugen/hypoxia models under both preventive and therapeutic regimens. CONCLUSIONS: These findings demonstrate that Omaveloxolone exerts disease-modifying effects in PH by activating NRF2-dependent cytoprotective pathways, reducing oxidative stress, and suppressing inflammation, supporting its translational potential as a therapeutic strategy.

Authors

Institutions

Publication Details

Journal
Hypertension
Published
2026-07-27
DOI
https://doi.org/10.1161/hypertensionaha.126.26711
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension

Shuxin Liang, Z Chen, June Bai, Haiyang Tang et al.
Hypertension
Pulmonary Hypertension Research and Treatments
article

Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension

Shuxin Liang, Z Chen, June Bai, Haiyang Tang, Deming Gou, Ang Luo, Caojin Zhang, Xingting Wang, Chuangjia Huang, Changlei Bao, Ankit A. Desai, Yingying Xiao, L. Dang, Jieyi Feng, Bitao Wu, Jintao Long, Zinan Luo, Hanliang Sun, Li Zhang, Jing Hua, Jinsheng Zhu, Li Li, Aiai Chu, Lei Yang
article en

Abstract

BACKGROUND: Pulmonary arterial hypertension is a progressive and life-threatening disorder characterized by elevated pulmonary arterial pressure, right ventricular hypertrophy, and eventual right heart failure. Omaveloxolone, an orally bioavailable synthetic triterpenoid recently approved for Friedreich's ataxia, improves mitochondrial bioenergetics and restores redox homeostasis. We investigated whether pharmacological activation of NRF2 (nuclear factor erythroid 2-related factor 2) by Omaveloxolone confers therapeutic benefit in pulmonary hypertension (PH). METHODS: The effects of Omaveloxolone were evaluated in chronic hypoxia-induced PH in mice, monocrotaline-induced PH in rats, and sugen/hypoxia-induced PH in rats, together with studies in human pulmonary artery endothelial and smooth muscle cells. RESULTS: NRF2 expression and nuclear localization were reduced in PH lungs and hypoxia-exposed cells, whereas Omaveloxolone restored NRF2 activity and increased downstream antioxidant enzymes. In endothelial cells, Omaveloxolone reduced oxidative stress, suppressed inflammatory signaling, and inhibited endothelial-to-mesenchymal transition. In smooth muscle cells, it attenuated oxidative stress and normalized abnormal proliferation, migration, and apoptosis. Omaveloxolone reduced HIF (hypoxia-inducible factor)-2α accumulation in endothelial cells and inhibited HIF-1α stabilization in smooth muscle cells. NRF2 knockdown attenuated these effects, supporting pathway dependency. Omaveloxolone attenuated PH, reduced right ventricular hypertrophy and vascular remodeling, and improved right ventricular function across hypoxia, monocrotaline, and sugen/hypoxia models under both preventive and therapeutic regimens. CONCLUSIONS: These findings demonstrate that Omaveloxolone exerts disease-modifying effects in PH by activating NRF2-dependent cytoprotective pathways, reducing oxidative stress, and suppressing inflammation, supporting its translational potential as a therapeutic strategy.

Hypertension
Jinan University (CN), Shenzhen University (CN), Guangdong Pharmaceutical University (CN), First Affiliated Hospital of Guangzhou Medical University (CN), Shanghai East Hospital (CN), Second Affiliated Hospital of Nanjing Medical University (CN), Guangdong Academy of Medical Sciences (CN), Indiana University – Purdue University Indianapolis (US), Guangzhou Medical University (CN)
Openalex Percentile: Top 10%
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.